Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 611,344
  • Shares Outstanding, K 57,135
  • Annual Sales, $ 40 K
  • Annual Income, $ -160,870 K
  • EBIT $ -230 M
  • EBITDA $ -233 M
  • 60-Month Beta 2.96
  • Price/Sales 17,279.48
  • Price/Cash Flow N/A
  • Price/Book 1.42

Options Overview Details

View History
  • Implied Volatility 90.60% (-35.12%)
  • Historical Volatility 75.66%
  • IV Percentile 5%
  • IV Rank 2.26%
  • IV High 721.01% on 04/10/25
  • IV Low 76.01% on 08/20/25
  • Expected Move (DTE 11) 1.96 (17.58%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 27
  • Volume Avg (30-Day) 105
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 3,757
  • Open Int (30-Day) 4,514
  • Expected Range 9.17 to 13.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.53
  • Number of Estimates 4
  • High Estimate 0.40
  • Low Estimate -1.05
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +41.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.78 +14.16%
on 11/10/25
11.89 -6.10%
on 11/28/25
+0.66 (+6.33%)
since 11/07/25
3-Month
6.47 +72.65%
on 09/22/25
12.34 -9.52%
on 10/28/25
+4.20 (+60.19%)
since 09/08/25
52-Week
2.23 +400.67%
on 04/09/25
12.34 -9.52%
on 10/28/25
+3.82 (+51.90%)
since 12/06/24

Most Recent Stories

More News
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 11.08 (+3.55%)
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The...

FDMT : 11.08 (+3.55%)
NBP : 4.05 (-3.11%)
AURA : 6.41 (-0.31%)
4DMT to Participate in 8th Annual Evercore Healthcare Conference

EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 11.08 (+3.55%)
4DMT Appoints Kristian Humer as Chief Financial Officer

EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 11.08 (+3.55%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 11.08 (+3.55%)
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive...

FDMT : 11.08 (+3.55%)
4DMT to Participate in Jefferies 2025 London Healthcare Conference

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 11.08 (+3.55%)
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 11.08 (+3.55%)
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time...

FDMT : 11.08 (+3.55%)
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration ...

FDMT : 11.08 (+3.55%)

Business Summary

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas....

See More

Key Turning Points

3rd Resistance Point 12.07
2nd Resistance Point 11.79
1st Resistance Point 11.24
Last Price 11.08
1st Support Level 10.41
2nd Support Level 10.13
3rd Support Level 9.58

See More

52-Week High 12.34
Last Price 11.08
Fibonacci 61.8% 8.48
Fibonacci 50% 7.28
Fibonacci 38.2% 6.09
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar